Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment
Sign Up to like & getrecommendations! Published in 2021 at "Oncogene"
DOI: 10.1038/s41388-021-02020-z
Abstract: The enzyme iodothyronine deiodinase type 3 (DIO3) contributes to cancer proliferation by inactivating the tumor-suppressive actions of thyroid hormone (T3). We recently established DIO3 involvement in the progression of high-grade serous ovarian cancer (HGSOC). Here… read more here.
Keywords: dio3; paradigm ovarian; ovarian cancer; dio3 enzyme ... See more keywords